PT  - JOURNAL ARTICLE
AU  - Dittadi, Ruggero
AU  - Afshar, Haleh
AU  - Carraro, Paolo
TI  - Early antibody response to SARS-CoV-2
AID  - 10.1101/2020.05.19.20099317
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.19.20099317
4099  - http://medrxiv.org/content/early/2020/05/22/2020.05.19.20099317.short
4100  - http://medrxiv.org/content/early/2020/05/22/2020.05.19.20099317.full
AB  - Background The role and significance of the immune response to SARS-CoV-2 infection is not yet well known.Methods We conducted a study on 46 symptomatic subjects with disease confirmed by laboratory tests, to evaluate the presence of IgG and IgM antibodies in these subjects in relation to the time elapsed since the onset of symptoms. The analytical performance of the method used in the study and the effect of two different serum and plasma matrices were also assessed.Results IgG positivity was demonstrated in 100% of cases 15 days after the onset of the disease. IgM show lower concentrations and do not exceed 77% of cases after 15 days. The analytical performance of the method used (Maglumi 800, Snibe, China) was confirmed to be good in terms of imprecision, linearity and commutability in two sample matrix.Conclusion The serological study through the search for specific IgG for SARS-CoV-2 results to be sensitive and suitable for population research and evidences that this approach can also play an important role in diagnosis.The diagnostic performance of specific IgMs are lower.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data of the present study are available